{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:54Z","timestamp":1786986894401,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-15397"],"award-info":[{"award-number":["IG-15397"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2010-2011"],"award-info":[{"award-number":["2010-2011"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clml.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T02:55:42Z","timestamp":1552272942000},"page":"678-685.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments"],"prefix":"10.1016","volume":"19","author":[{"given":"Andrea","family":"Visentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Facco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Gurrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Imbergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Frezzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Trimarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-9656","authenticated-orcid":false,"given":"Filippo","family":"Severin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Scomazzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pravato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2831-623X","authenticated-orcid":false,"given":"Francesco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-4595","authenticated-orcid":false,"given":"Gianpietro","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.002_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Scarfo","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2019.03.002_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.002_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.002_bib4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.clml.2015.06.001","article-title":"Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia","volume":"15","author":"Visentin","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.03.002_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/ajh.24808","article-title":"IGHV mutational status testing in chronic lymphocytic leukemia","volume":"92","author":"Crombie","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.002_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clml.2016.11.008","article-title":"Change in IgHV mutational status of CLL suggests origin from multiple clones","volume":"17","author":"Osman","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.03.002_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib10","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.002_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2016.03.069","article-title":"Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials","volume":"60","author":"Gentile","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2019.03.002_bib12","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.002_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.15018","article-title":"The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab","volume":"180","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.002_bib14","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment","volume":"90","author":"Hallek","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.002_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/leu.2011.49","article-title":"Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases","volume":"25","author":"Langerak","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.002_bib17","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2012.25","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","volume":"26","author":"Pospisilova","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.002_bib18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdy021","article-title":"Genetic landscape of ultra-stable chronic lymphocytic leukemia patients","volume":"29","author":"Raponi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.03.002_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.leu.2404607","article-title":"Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome","volume":"21","author":"Terrin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.002_bib20","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.03.002_bib22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.002_bib23","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib24","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1002\/ajh.25206","article-title":"Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases","volume":"93","author":"Morabito","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.002_bib25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hon.2343","article-title":"Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia","volume":"35","author":"Visentin","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.03.002_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2016.11.020","article-title":"Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients","volume":"72","author":"Visentin","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2019.03.002_bib27","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.3324\/haematol.2015.126763","article-title":"Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy","volume":"100","author":"Visentin","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.03.002_bib28","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.002_bib29","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.002_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-120779","volume":"132","author":"Shanafelt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib31","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib32","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.002_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3324\/haematol.2018.189837","article-title":"Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study","volume":"103","author":"Cuneo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.03.002_bib34","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.002_bib35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.leu.2404607","article-title":"Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same IGVH mutation status and different outcome","volume":"21","author":"Terrin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.002_bib36","doi-asserted-by":"crossref","first-page":"W503","DOI":"10.1093\/nar\/gkn316","article-title":"IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis","volume":"36","author":"Brochet","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clml.2019.03.002_bib37","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.002_bib38","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1093\/bioinformatics\/btv456","article-title":"ARResT\/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy","volume":"31","author":"Bystry","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.clml.2019.03.002_bib39","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018317634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018317634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:35Z","timestamp":1761870815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018317634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2152265018317634"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}